title: Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
abstract: OBJECTIVE
  The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized.
  
  
  METHODS
  We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI).
  
  
  RESULTS
  From this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor.
  
  
  CONCLUSIONS
  CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity.
authors.affiliation: Cancer Vaccine Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Skin Disease Research Center, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: Wandi
authors.initials: W
authors.lastname: Zhang
authors.forename: Jaewon
authors.initials: J
authors.lastname: Choi
authors.forename: Wanyong
authors.initials: W
authors.lastname: Zeng
authors.forename: Shelby A
authors.initials: SA
authors.lastname: Rogers
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.forename: James G
authors.initials: JG
authors.lastname: Rheinwald
authors.forename: Christine M
authors.initials: CM
authors.lastname: Canning
authors.forename: Vladimir
authors.initials: V
authors.lastname: Brusic
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Sasada
authors.forename: Ellis L
authors.initials: EL
authors.lastname: Reinherz
authors.forename: Jerome
authors.initials: J
authors.lastname: Ritz
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Wu
mesh_terms: D017951:Antigen Presentation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation / Q000276:immunology; D017710:Lymphocyte Transfusion; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000628:therapy; D016133:Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D018984:Epitopes, T-Lymphocyte; D006680:HLA Antigens; C431278:NUDCD1 protein, human
references.citation: Blood. 2005 Mar 1;105(5):2132-4
references.pmid: 15561890
references.citation: Blood. 1993 Feb 15;81(4):1089-93
references.pmid: 8427990
references.citation: Immunity. 1998 Mar;8(3):363-72
references.pmid: 9529153
references.citation: Blood. 2002 Jul 15;100(2):701-3
references.pmid: 12091369
references.citation: Blood. 2009 Mar 5;113(10):2238-44
references.pmid: 18997173
references.citation: Cancer Sci. 2008 Jul;99(7):1414-9
references.pmid: 18422754
references.citation: Eur J Immunol. 2007 Nov;37(11):3063-8
references.pmid: 17960663
references.citation: Cancer Res. 2003 Sep 1;63(17):5582-6
references.pmid: 14500398
references.citation: Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52
references.pmid: 17517626
references.citation: J Clin Invest. 2000 Sep;106(5):705-14
references.pmid: 10974024
references.citation: Blood. 2001 Aug 15;98(4):1116-21
references.pmid: 11493459
references.citation: Blood. 1997 Sep 1;90(5):2103-8
references.pmid: 9292550
references.citation: Curr Biol. 2006 Jul 25;16(14):1414-21
references.pmid: 16860740
references.citation: Br J Haematol. 2009 Jun;146(1):115-8
references.pmid: 19388930
references.citation: Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8200-4
references.pmid: 7545296
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4759-68
references.pmid: 19567591
references.citation: Nat Med. 2004 Sep;10(9):909-15
references.pmid: 15340416
references.citation: Blood. 2007 Feb 15;109(4):1355-62
references.pmid: 17008540
references.citation: J Clin Oncol. 1997 Feb;15(2):433-44
references.pmid: 9053463
references.citation: Blood. 2002 Jun 15;99(12):4610-7
references.pmid: 12036895
references.citation: Blood. 2004 Jan 15;103(2):656-63
references.pmid: 14563636
references.citation: Blood. 2005 May 15;105(10):3945-50
references.pmid: 15692072
references.citation: Med Immunol. 2006 May 18;5:1
references.pmid: 16674822
references.citation: PLoS One. 2007 Aug 29;2(8):e796
references.pmid: 17726526
references.citation: Blood. 2007 Mar 1;109(5):2001-7
references.pmid: 17068145
references.citation: Blood. 2000 Jan 1;95(1):352-9
references.pmid: 10607724
references.citation: Clin Cancer Res. 2009 Aug 1;15(15):4944-53
references.pmid: 19602548
references.citation: J Immunol. 2005 Feb 1;174(3):1269-73
references.pmid: 15661882
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5323-37
references.pmid: 19723653
references.citation: J Immunol. 2005 Jun 15;174(12):8210-8
references.pmid: 15944330
references.citation: J Clin Invest. 2008 Jan;118(1):294-305
references.pmid: 18060041
references.citation: Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7
references.pmid: 11416219
references.citation: J Virol. 2003 Apr;77(8):4911-27
references.pmid: 12663797
references.citation: Immunogenetics. 1999 Nov;50(3-4):213-9
references.pmid: 10602881
references.citation: Nat Med. 2003 Sep;9(9):1151-7
references.pmid: 12910264
references.citation: J Clin Invest. 1997 Aug 15;100(4):855-66
references.pmid: 9259585
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4515-7
references.pmid: 19584145
references.citation: Immunol Rev. 2008 Apr;222:357-68
references.pmid: 18364014
references.citation: Adv Immunol. 2006;90:133-73
references.pmid: 16730263
references.citation: Blood. 1995 Sep 1;86(5):2041-50
references.pmid: 7655033
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42
references.pmid: 17652518
references.citation: Exp Hematol. 2008 Sep;36(9):1205-15
references.pmid: 18550258
references.citation: J Exp Med. 2002 Jan 7;195(1):F1-3
references.pmid: 11781374
references.citation: Clin Cancer Res. 2005 Jun 15;11(12):4504-11
references.pmid: 15958636